(0.33%) 5 117.03 points
(0.33%) 38 365 points
(0.37%) 15 988 points
(-0.98%) $83.03
(5.56%) $2.03
(0.34%) $2 355.20
(0.46%) $27.66
(4.03%) $959.25
(-0.25%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 3.43%
@ $38.14
発行日: 14 2月 2024 @ 23:30
リターン: -10.15%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -0.52 %
Live Chart Being Loaded With Signals
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada...
Stats | |
---|---|
本日の出来高 | 16 578.00 |
平均出来高 | 61 162.00 |
時価総額 | 817.49M |
EPS | $0 ( 2024-02-13 ) |
次の収益日 | ( $0 ) 2024-04-30 |
Last Dividend | $0.120 ( 2023-12-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.42 |
ATR14 | $0.0840 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Stacy Linda | Buy | 0 | |
2024-03-27 | Nunnelly John N | Buy | 9 259 | Common Stock |
2024-03-27 | Nunnelly John N | Sell | 3 487 | Common Stock |
2024-03-27 | Nunnelly John N | Sell | 9 259 | Director Stock Option (Right to Buy) |
2024-03-01 | Common Property Trust | Sell | 598 653 | Common Stock |
INSIDER POWER |
---|
-90.75 |
Last 96 transactions |
Buy: 143 501 | Sell: 1 953 935 |
ボリューム 相関
National Research Corp 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
National Research Corp 相関 - 通貨/商品
National Research Corp 財務諸表
Annual | 2023 |
収益: | $148.58M |
総利益: | $86.67M (58.33 %) |
EPS: | $1.260 |
FY | 2023 |
収益: | $148.58M |
総利益: | $86.67M (58.33 %) |
EPS: | $1.260 |
FY | 2022 |
収益: | $151.57M |
総利益: | $94.52M (62.36 %) |
EPS: | $1.280 |
FY | 2021 |
収益: | $147.95M |
総利益: | $95.60M (64.62 %) |
EPS: | $1.473 |
Financial Reports:
No articles found.
National Research Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.240 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$1.120 (N/A) |
$0.120 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0600 | 2014-12-29 |
Last Dividend | $0.120 | 2023-12-28 |
Next Dividend | $0 | N/A |
Payout Date | 2024-01-12 | |
Next Payout Date | N/A | |
# dividends | 35 | -- |
Total Paid Out | $6.34 | -- |
Avg. Dividend % Per Year | 1.58% | -- |
Score | 4.63 | -- |
Div. Sustainability Score | 8.98 | |
Div.Growth Potential Score | 5.35 | |
Div. Directional Score | 7.16 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0.0600 | 0.32% |
2015 | $0.620 | 4.48% |
2016 | $0.340 | 2.23% |
2017 | $0.400 | 2.13% |
2018 | $1.130 | 3.07% |
2019 | $0.780 | 2.04% |
2020 | $0.210 | 0.32% |
2021 | $0.480 | 1.12% |
2022 | $0.840 | 1.99% |
2023 | $1.480 | 3.80% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.208 | 1.500 | 5.83 | 8.75 | [0 - 0.5] |
returnOnAssetsTTM | 0.253 | 1.200 | 1.568 | 1.882 | [0 - 0.3] |
returnOnEquityTTM | 0.478 | 1.500 | 5.80 | 8.70 | [0.1 - 1] |
payoutRatioTTM | 1.174 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.673 | 0.800 | -1.636 | -1.309 | [1 - 3] |
quickRatioTTM | 0.532 | 0.800 | -1.574 | -1.259 | [0.8 - 2.5] |
cashRatioTTM | 0.184 | 1.500 | -0.0902 | -0.135 | [0.2 - 2] |
debtRatioTTM | 0.305 | -1.500 | 4.92 | -7.39 | [0 - 0.6] |
interestCoverageTTM | 46.46 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.560 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.914 | 2.00 | 9.54 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.762 | -1.500 | 6.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.613 | 1.000 | 3.11 | 3.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.270 | 1.000 | 6.61 | 6.61 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.022 | 1.000 | 5.43 | 5.43 | [0.2 - 2] |
assetTurnoverTTM | 1.214 | 0.800 | 5.24 | 4.19 | [0.5 - 2] |
Total Score | 8.98 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 26.68 | 1.000 | 7.41 | 0 | [1 - 100] |
returnOnEquityTTM | 0.478 | 2.50 | 7.30 | 8.70 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.914 | 2.00 | 9.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.38 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.560 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.174 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -5.87 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.257 | 1.000 | 6.09 | 0 | [0.1 - 0.5] |
Total Score | 5.35 |
National Research Corp
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。